Page last updated: 2024-10-24
busulfan and Skin Neoplasms
busulfan has been researched along with Skin Neoplasms in 16 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 9.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 9.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 7.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 5.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 5.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "30) versus busulfan-based myeloablative regimens; were diagnosed with acute graft-versus-host disease (GVHD) with stage 2+ skin involvement (OR = 1." | 3.96 | Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. ( Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA, 2020) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 3.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| "In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma." | 3.72 | The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. ( Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004) |
| "Treatment with Busulfan plus Fludarabine depleted lymphocytes only weakly." | 2.75 | Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. ( Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V, 2010) |
| " The dose-response relationships between BUS and SCEs in vitro were found to be similar for bone marrow and lymphocytes." | 1.26 | Spontaneous and busulphan-induced sister-chromatid exchange (SCE) frequencies in haematologically normal human bone marrow and lymphocytes. ( Honeycombe, JR, 1981) |
Research
Studies (16)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Herr, MM | 1 |
| Curtis, RE | 1 |
| Tucker, MA | 1 |
| Tecca, HR | 1 |
| Engels, EA | 1 |
| Cahoon, EK | 1 |
| Battiwalla, M | 1 |
| Buchbinder, D | 1 |
| Flowers, ME | 1 |
| Brazauskas, R | 1 |
| Shaw, BE | 1 |
| Morton, LM | 1 |
| Atzpodien, J | 2 |
| Terfloth, K | 2 |
| Fluck, M | 2 |
| Reitz, M | 2 |
| Laurent, J | 1 |
| Speiser, DE | 1 |
| Appay, V | 1 |
| Touvrey, C | 1 |
| Vicari, M | 1 |
| Papaioannou, A | 1 |
| Canellini, G | 1 |
| Rimoldi, D | 1 |
| Rufer, N | 1 |
| Romero, P | 1 |
| Leyvraz, S | 1 |
| Voelter, V | 1 |
| Neuber, K | 3 |
| Reinhold, U | 2 |
| Deutschmann, A | 1 |
| Pföhler, C | 2 |
| Mohr, P | 1 |
| Pichlmeier, U | 1 |
| Baumgart, J | 1 |
| Hauschild, A | 2 |
| Knight, LA | 1 |
| Di Nicolantonio, F | 1 |
| Whitehouse, P | 1 |
| Mercer, S | 1 |
| Sharma, S | 1 |
| Glaysher, S | 1 |
| Johnson, P | 1 |
| Cree, IA | 2 |
| Corrie, PG | 1 |
| Shaw, J | 1 |
| Spanswick, VJ | 1 |
| Sehmbi, R | 1 |
| Jonson, A | 1 |
| Mayer, A | 1 |
| Bulusu, R | 1 |
| Hartley, JA | 1 |
| Mauch, C | 1 |
| Ugurel, S | 1 |
| Schadendorf, D | 1 |
| Thoelke, A | 1 |
| Ulrich, J | 1 |
| Spieth, K | 1 |
| Kaatz, M | 1 |
| Rittgen, W | 1 |
| Delorme, S | 1 |
| Tilgen, W | 1 |
| Koliadenko, VG | 1 |
| Shupen'ko, NM | 1 |
| Shmyglo, MP | 1 |
| Honeycombe, JR | 1 |
| Salmon-Ehr, V | 1 |
| Grosieux, C | 1 |
| Potron, G | 1 |
| Kalis, B | 1 |
| Sugiura, K | 1 |
| Misra, RC | 1 |
| Rakshit, MM | 1 |
| Basu, AK | 1 |
| Bernadou, A | 1 |
| Clauvel, JP | 1 |
| Antebi, L | 1 |
| Bilski-Pasquier, G | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma[NCT00779714] | Phase 3 | 360 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
6 trials available for busulfan and Skin Neoplasms
| Article | Year |
|---|---|
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Fema | 2010 |
Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; B | 2003 |
Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Disease Progression; Fe | 2003 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; D | 2005 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2006 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2007 |
Other Studies
10 other studies available for busulfan and Skin Neoplasms
| Article | Year |
|---|---|
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Femal | 2020 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2011 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
[Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2005 |
[Case of mycosis fungoides treated with myelosan].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Busulfan; Humans; Male; Middle Aged; Mycosis Fungoid | 1983 |
Spontaneous and busulphan-induced sister-chromatid exchange (SCE) frequencies in haematologically normal human bone marrow and lymphocytes.
Topics: Adult; Aged; Bone Marrow; Breast Neoplasms; Busulfan; Carcinoma; Cells, Cultured; Chromosomes; Cross | 1981 |
Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment.
Topics: Aged; Antineoplastic Agents; Busulfan; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydr | 1998 |
Chemotherapy of induced skin tumors in mice.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Benz(a)Anthracenes; Busulfan; Ca | 1968 |
Subcutaneous leukaemic deposit in chronic myelogenous leukaemia--course and histological appearance.
Topics: Busulfan; Female; Humans; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; | 1973 |
[Vaquez's diseas. Clinical and developmental study. Apropos of 144 cases].
Topics: Adult; Arteriosclerosis; Arteritis; Blood Sedimentation; Busulfan; Child; Erythrocyte Count; Female; | 1968 |